Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with a history of hormone receptor-negative breast cancer.
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2014
At a glance
- Drugs Polyphenon E (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Biomarker
- 10 Jun 2017 Biomarkers information updated
- 21 Jun 2012 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 15 Nov 2011 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.